DelveInsight’s “Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Systemic Lupus Erythematosus market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Systemic Lupus Erythematosus drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Systemic Lupus Erythematosus treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Systemic Lupus Erythematosus: An Overview
According to the American College of Rheumatology, Systemic lupus erythematosus, referred to as SLE is a chronic (long-term) disease that causes systemic inflammation that affects multiple organs. In addition to affecting the skin and joints, it can affect other organs in the body such as the kidneys, the tissue lining the lungs (pleura), the heart (pericardium), and the brain. Many patients experience fatigue, weight loss, and fever. The times when symptoms get worse are called relapses, or flares. The times when symptoms are under control are called remissions. The general symptoms are not specific. Lupus flares vary from mild to serious. SLE is most commonly seen in women in the reproductive age group (frequently starting at childbearing age), although lupus is increasingly recognized after the age of 40 years, particularly in Europeans.
The Lupus Foundation of America (2016) estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus, and systemic lupus accounts for approximately 70% of all cases. Ninety percent (90%) of people living with lupus are women, and most people with lupus develop the disease between the ages of 15–44.
There is no complete cure for SLE currently, but there are many treatments available to help with particular symptoms. The disease involves a wide range of clinical features that encompasses vascular, immune, and fibrotic manifestations along with the involvement of many organs.
Systemic Lupus Erythematosus Market Key Facts
-
Among the 7MM, the United States accounted for the highest number of diagnosed prevalent cases. The total prevalent cases of Systemic Lupus Erythematosus in the US were ~360,000 in 2022.
-
Among EU4 countries, Germany had the highest number of diagnosed prevalent cases of Systemic Lupus Erythematosus, while Spain had the lowest number of diagnosed prevalent cases.
-
Japan accounted for ~10% of Systemic Lupus Erythematosus cases among the 7MM in 2022.
-
According to DelveInsight estimates, based on the age-specific cases of SLE, the 40-59 years age group contributed the highest percentage across the 7MM.
Systemic Lupus Erythematosus Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Systemic Lupus Erythematosus pipeline therapies. It also thoroughly assesses the Systemic Lupus Erythematosus market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Systemic Lupus Erythematosus drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Systemic Lupus Erythematosus Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Systemic Lupus Erythematosus epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Systemic Lupus Erythematosus epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Systemic Lupus Erythematosus Epidemiology, Segmented as –
-
Total Diagnosed Prevalent Cases of SLE in the 7MM [2019-2032]
-
Age-specific Diagnosed Prevalent Cases of SLE in the 7MM [2019-2032]
-
Severity-specific Diagnosed Prevalent Cases of SLE in the 7MM [2019-2032]
-
Gender-specific Diagnosed Prevalent Cases of SLE in the 7MM [2019-2032]
Systemic Lupus Erythematosus Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Systemic Lupus Erythematosus market or expected to be launched during the study period. The analysis covers the Systemic Lupus Erythematosus market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Systemic Lupus Erythematosus drugs based on their sale and market share.
The report also covers the Systemic Lupus Erythematosus pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Systemic Lupus Erythematosus companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Systemic Lupus Erythematosus Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-market
Systemic Lupus Erythematosus Therapeutics Analysis
There is no complete cure for SLE currently, but there are many treatments available to help with particular symptoms. The disease involves a wide range of clinical features that encompasses vascular, immune, and fibrotic manifestations along with the involvement of many organs.
Treatments for SLE include NSAIDs and antimalarial agents, which are the first-line therapies for mild SLE. In addition, glucocorticoids and cytotoxic or immunosuppressive agents—such as azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporine, and methotrexate —are used for SLE with organ involvement.
The current market possesses approved products such as BENLYSTA (belimumab) and SAPHNELO (anifrolumab-fnia).
Several major pharma and biotech companies are developing therapies for Systemic Lupus Erythematosus. Currently, Roche is leading the therapeutics market with its Systemic Lupus Erythematosus drug candidates in the most advanced stage of clinical development.
Systemic Lupus Erythematosus Companies Actively Working in the Therapeutics Market Include
AbbVie, Akeso Biopharma, Alpine Immune Sciences, Amgen, Antengene Therapeutics, Aria Pharmaceuticals, Asahi Kasei Pharma, Athos Therapeutics, Biogen, Boston Pharmaceuticals, Brickell Biotech, Bristol-Myers Squibb, Carna Bioscience, Chipscreen Biosciences, Citryll BV, Corbus Pharmaceuticals, Corestem, Daiichi Sankyo Company, Eisai, Eli Lilly and Company, Equillium, Exinda Thearapeutics, Genovax, Horizon Therapeutics, I-MAB Biopharma, Idorsia Pharmaceuticals, ILTOO, ImmuPharma, InnoCare, Janssen, Janssen Research & Development, Kangpu Biopharmaceuticals, Kezar Life Sciences, Landos Biopharma, Medsenic, Merck KGaA, Neovacs, Novartis Pharmaceuticals, Pfizer, Provention Bio, Resolve, Resolve Therapeutics, Rheos Medicine, Roche, Sanofi, Sareum, Shanghai Junshi Biosciences, SinoMab Bioscience Ltd, Sorrento Therapeutics, UCB, Yake Biotechnology, and many others.
Emerging and Marketed Systemic Lupus Erythematosus Therapies Covered in the Report Include:
-
Obinutuzumab (Gazyva): Roche
-
Dapirolizumab pegol: UCB
-
BIIB059: Biogen
-
PRV 3279: Provention Bio
-
ABBV-599: AbbVie
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Systemic Lupus Erythematosus Competitive Intelligence Analysis
4. Systemic Lupus Erythematosus Market Overview at a Glance
5. Systemic Lupus Erythematosus Disease Background and Overview
6. Systemic Lupus Erythematosus Patient Journey
7. Systemic Lupus Erythematosus Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Systemic Lupus Erythematosus Treatment Algorithm, Current Treatment, and Medical Practices
9. Systemic Lupus Erythematosus Unmet Needs
10. Key Endpoints of Systemic Lupus Erythematosus Treatment
11. Systemic Lupus Erythematosus Marketed Therapies
12. Systemic Lupus Erythematosus Emerging Drugs and Latest Therapeutic Advances
13. Systemic Lupus Erythematosus Seven Major Market Analysis
14. Attribute Analysis
15. Systemic Lupus Erythematosus Market Outlook (In US, EU5, and Japan)
16. Systemic Lupus Erythematosus Companies Active in the Market
17. Systemic Lupus Erythematosus Access and Reimbursement Overview
18. KOL Views on the Systemic Lupus Erythematosus Market
19. Systemic Lupus Erythematosus Market Drivers
20. Systemic Lupus Erythematosus Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Polypoidal Choroidal Vasculopathy Market
“Polypoidal Choroidal Vasculopathy (PCV) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Polypoidal Choroidal Vasculopathy market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Polypoidal Choroidal Vasculopathy market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology